Celyad SA Company Profile (NASDAQ:CYAD)

Analyst Ratings

Consensus Ratings for Celyad SA (NASDAQ:CYAD) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $95.00 (280.00% upside)

Analysts' Ratings History for Celyad SA (NASDAQ:CYAD)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016Piper Jaffray Cos.Reiterated RatingOverweight$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Maxim GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Celyad SA (NASDAQ:CYAD)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Celyad SA (NASDAQ:CYAD)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Celyad SA (NASDAQ:CYAD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celyad SA (NASDAQ:CYAD)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Celyad SA (NASDAQ:CYAD)
DateHeadline
07/27/16 09:52 AMCelyad SA :CYAD-US: Earnings Analysis: For the six months ended December 31, 2015 : July 27, 2016 -
07/22/16 02:34 AMCelyad SA :CYAD-BE: Earnings Analysis: For the six months ended December 31, 2015 : July 22, 2016 -
07/22/16 01:11 AMCelyad SA :CYAD-BE: Earnings Analysis: 2015 By the Numbers : July 22, 2016 -
07/20/16 08:51 AMCelyad SA (ADR) (NASDAQ:CYAD): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:51 AMCelyad SA Ads (NASDAQ:CYAD) Sellers Increased By 13.81% Their Shorts - Consumer Eagle
07/18/16 08:35 AMTrading Performance and Target Watch for Celyad SA (ADR) (NASDAQ:CYAD) - Press Telegraph
07/17/16 03:18 PMCelyad SA (CYAD) Broker Price Targets For The Coming Week - Fiscal Standard
07/14/16 09:01 PMCelyad : successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial
07/14/16 09:01 PMCELYAD S.A.: Celyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial
07/14/16 06:16 AMCelyad SA Ads (NASDAQ:CYAD) Short Interest Increased By 8.67% - Consumer Eagle
07/14/16 12:48 AMCelyad successfully completes safety follow-up of the first patient at the fourth dose level in the NKR-2 Phase I trial - [at noodls] - No safety issues or dose limiting toxicity reported in the first patient at the fourth dose level. Next patient, 11of the trial, has been infused. The trial is a dose escalation study evaluating safety ...
07/12/16 03:41 PMCelyad SA (ADR) (NASDAQ:CYAD) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 03:32 PMCELYAD S.A.: Celyad enters into license agreement with ONO PHARMACEUTICAL CO., LTD. to develop allogeneic NKR-2 T-cell immunotherapy
07/11/16 03:32 PMCelyad SA (CYAD) Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunotherapy
07/11/16 08:20 AMCelyad SA (CYAD) Enters Licensing Agreement with ONO Pharma for NKR-2 T-cell Immunotherapy - StreetInsider.com
07/08/16 09:02 AMWeekly Biotech Report Covering Gilead Sciences, Inc. (GILD) and Celyad SA (ADR) (CYAD) - Insider Monkey (blog)
07/07/16 01:52 PMWeekly Biotech Report Covering Gilead Sciences, Inc. (GILD) and Celyad SA (ADR) (CYAD) -
07/07/16 08:47 AMCelyad SA (CYAD) Current Analyst Ratings - Fiscal Standard
07/01/16 08:39 PMANTH Dims On BRIGHT-SC Data, CYAD Fails To Chart, LLY Gets FDA Panel Nod - Nasdaq
06/30/16 09:31 AMCelyad SA Ads (NASDAQ:CYAD) Shorted Shares Increased 8.67% After Market Selling - Engelwood Daily
06/30/16 09:31 AMBrokers Issue Average Price Target Of 87.00 On Celyad SA (CYAD) - Fiscal Standard
06/29/16 08:32 PMNew Broker Ratings For Celyad SA (CYAD) - FTSE News
06/29/16 03:28 PMCelyad SA (CYAD) Says CHART-1 Trial Results Not Statistically Significant
06/28/16 08:39 PM7 Biggest Mid-Day Losers For Tuesday - Benzinga
06/28/16 08:39 PMNext Weeks Broker Price Targets For Celyad SA (CYAD) - Fiscal Standard
06/28/16 08:39 PMCelyad SA (EBR:CYAD)'s Company Shares Decreased 16.62% After Low Volatility - Press Telegraph
06/28/16 08:39 PMCelyad SA (CYAD) Says CHART-1 Trial Results Not Statistically Significant - StreetInsider.com
06/28/16 03:30 PMCELYAD S.A.: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy
06/28/16 05:11 AMCelyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure® Cell Therapy - [at noodls] - A statistically-significant difference on the primary endpoint was not reached; however, a positive trend was seen across all treatment groups, and the primary endpoint was met (p=0.015) for a subset representing ...
06/23/16 02:04 AM3:04 am Celyad reports infusion of the first patient enrolled in the fourth dose level of its Phase I/IIa clinical trial -
06/23/16 12:09 AMCelyad treats first patient in the fourth dose level of its NKR-2 trial - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, today announced the infusion of the first patient ...
06/14/16 08:20 AMCelyad : appoints Graham Morrell as Vice-President of Investors Relations & Communication
06/14/16 12:09 AMCelyad appoints Graham Morrell as Vice-President of Investors Relations & Communication - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
06/06/16 08:56 PMCelyad : appoints Dr. David Gilham as Vice-President of Research & Development
06/06/16 12:08 AMCelyad appoints Dr. David Gilham as Vice-President of Research & Development - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
06/01/16 10:04 AMCelyad: CAR Reaches The Highest Dose - Celyad SA (NASDAQ:CYAD) can now move to the highest planned dose of 3x107 cells in the important NKR-2 Phase II CAR trial. If the next 30m cell dose is also safe (and the MTD) it will lead to two separate six patient open label studies in Acute Myeloid ...
05/26/16 12:07 AMCelyad successfully completes safety follow-up of the third dose level of its NKR-2 Trial - [at noodls] - The trial is a dose escalation study evaluating safety and feasibility of NKR-2 T-cell therapy in patients with Acute Myeloid Leukemia or Multiple Myeloma. No dose limiting toxicity reported in the last ...
05/24/16 02:00 PMNext Weeks Broker Price Targets For Celyad SA (CYAD) - Share Trading News - Next Weeks Broker Price Targets For Celyad SA (CYAD)Share Trading NewsCelyad SA has a 50 day moving average of 48.16 and a 200 day moving average of 44.60. The stock's market capitalization is 448.89M, it has a 52-week low of 32.00 and a 52-week high of 67.94. The share price of the company (CYAD) was down -3.60%, ...
05/24/16 02:00 PMEarnings Review and Stock Rundown for Celyad SA (ADR) (NASDAQ:CYAD) - Wall Street Hints and News - Earnings Review and Stock Rundown for Celyad SA (ADR) (NASDAQ:CYAD)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Celyad SA (ADR) (NASDAQ:CYAD) to post ...and more »
05/19/16 12:02 AMCelyad announces first quarter 2016 business update - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
05/11/16 01:48 PMConsensus Rating Review for Celyad SA (ADR) (NASDAQ:CYAD) - B.O.D.Y Confidential - Consensus Rating Review for Celyad SA (ADR) (NASDAQ:CYAD)B.O.D.Y ConfidentialEquity research analysts currently have a consensus rating of 1 on shares of Celyad SA (ADR) (NASDAQ:CYAD). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, or Hold ...and more »
05/10/16 02:00 PMCelyad SA Ads (NASDAQ:CYAD) Sellers Increased By 66.18% Their Shorts - B.O.D.Y Confidential - Celyad SA Ads (NASDAQ:CYAD) Sellers Increased By 66.18% Their ShortsB.O.D.Y ConfidentialThe stock of Celyad SA Ads (NASDAQ:CYAD) registered an increase of 66.18% in short interest. CYAD's total short interest was 45,200 shares in May as published by FINRA. Its up 66.18% from 27,200 shares, reported previously. With 4,400 shares average ...
05/04/16 01:24 PMAverage Analyst Rating for Celyad SA (ADR) (NASDAQ:CYAD) - B.O.D.Y Confidential - Average Analyst Rating for Celyad SA (ADR) (NASDAQ:CYAD)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Celyad SA (ADR) (NASDAQ:CYAD) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/04/16 12:10 AMCelyad Announces Oral Presentation on NKR-2 T Cells Manufacturing for a First-in-Human Clinical Trial in AML and Multiple Myeloma - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular diseases ...
04/26/16 12:08 AMCelyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA) - [at noodls] - Mont-Saint-Guibert, Belgium - Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease ...
04/23/16 01:37 PMCelyad SA (ADR) (NASDAQ:CYAD) Share Rating Recap - The Post - Celyad SA (ADR) (NASDAQ:CYAD) Share Rating RecapThe PostShares of Celyad SA (ADR) (NASDAQ:CYAD) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from financial ...and more »
04/19/16 08:45 AMCelyad SA :CYAD-US: Earnings Analysis: For the six months ended December 31, 2015 -
04/19/16 08:27 AMCelyad SA :CYAD-US: Earnings Analysis: 2015 By the Numbers -
04/16/16 01:09 PMCelyad SA (ADR) (NASDAQ:CYAD): Quick Look at Earnings - News Tribune - Celyad SA (ADR) (NASDAQ:CYAD): Quick Look at EarningsNews TribuneWhen Celyad SA (ADR) (NASDAQ:CYAD) issues their next quarterly report on or near N/A, Wall Street analysts are predicting they will report earnings per share of $N/A. This consensus EPS number is provided by Zacks Research, which might differ from ...and more »
04/16/16 01:09 PMCelyad SA (ADR) (NASDAQ:CYAD) Analyst Recommendation Outlook - Clinton Financial - Celyad SA (ADR) (NASDAQ:CYAD) Analyst Recommendation OutlookClinton FinancialCovering analysts usually give Buy, Sell and Hold recommendations along with guidance and company earnings estimates. There are 2 analysts providing ratings for Celyad SA (ADR) (NASDAQ:CYAD). 3 have given the stock a “Strong Buy”, 0 rate it a “Buy”, ...Celyad SA Ads (NASDAQ:CYAD) Sellers Increased By 63.86% Their ShortsFranklin Independentall 2 news articles »

Social

About Celyad SA

Celyad SA logoCelyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company's product, C-Cure, allows the differentiation of a patient's own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYAD
  • CUSIP:
Key Metrics:
  • Previous Close: $25.00
  • 50 Day Moving Average: $33.62
  • 200 Day Moving Average: $41.61
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $232.83M
  • Current Year EPS Consensus Estimate: $-5.02 EPS
  • Next Year EPS Consensus Estimate: $-4.44 EPS
Additional Links:
Celyad SA (NASDAQ:CYAD) Chart for Thursday, July, 28, 2016